Adverse events in patients with chronic hypersensitivity pneumonitis receiving immunosuppression

Treatment#EventsExposure monthsIncidenceUnadjustedAdjusted
IRR (95% CI)p-value+IRR (95% CI)p-value+
 PRED (n=41)104525.370.198Ref.Ref.Ref.Ref.
 MMF (n=32)30401.830.0750.30 (0.15–0.58)<0.0010.34 (0.17–0.67)0.002
 AZA (n=20)45505.830.0890.48 (0.23–0.97)0.0400.46 (0.21–0.98)0.044
 PRED (n=41)8525.370.015Ref.Ref.Ref.Ref.
 MMF (n=32)8401.830.0201.19 (0.38–3.78)0.7671.22 (0.35–4.33)0.755
 AZA (n=20)8505.830.0161.40 (0.27–7.33)0.6890.84 (0.18–3.97)0.829

IRR: incidence rate ratio; TEAE: treatment-emergent adverse event; PRED: prednisone; MMF: mycophenolate mofetil; AZA: azathioprine; SAE: serious adverse event. #: patients receiving MMF or AZA also had concurrent therapy with low-dose PRED. : for age, sex, race, forced vital capacity (% predicted), diffusing capacity of the lung for carbon monoxide (% predicted) and identified antigen. +: versus PRED. §: MMF TEAEs were constipation, nausea, vomiting, headache, dizziness, blurry vision, diarrhoea, stomach upset/pain, flatulence/bloating/dyspepsia, oedema, hypertension, fever, tremors, insomnia, petechiae/bruising, cellulitis, recurrent urinary tract infections and lower respiratory tract infections; PRED TEAEs were appetite changes, nausea, vomiting, hypokalaemia, headache, dizziness, blurry vision, glucose intolerance, stomach upset/pain, flatulence/dyspepsia, oedema, sodium retention, hypertension, fever, diaphoresis, tremors, insomnia, petechiae/bruising, cellulitis, skin atrophy, impaired wound healing, facial erythema, skin pigmentation, hair loss, acne, rash, urticaria, emotional lability, anxiety, depression, raised intraocular pressure, Cushing's syndrome/moon facies, hirsutism, menstrual irregularities, muscle atrophy/deconditioning/proximal myopathy, osteopenia/osteoporosis, cataracts, glaucoma, thrush, recurrent urinary tract infections and lower respiratory tract infections. ƒ: death, lung transplant or respiratory hospitalisation.